Temasek-backed biotech firm Abbisko raises US$123m from Carlyle, Warburg
Add BT as a preferred source[HONG KONG] Chinese biotech company Abbisko Therapeutics Co has raised US$123 million from more than a dozen investors, including Carlyle Group and Warburg Pincus, in its latest funding round, the company said on Friday.
Abbisko said in a press statement that Carlyle led the latest fundraising with Warburg, OrbiMed, Lake Bleu Capital and an unnamed Boston-based investor as the joint leading investors.
Other investors include Janchor Partners, Sage Partners, SHC and Greater Bay Area Homeland Development Fund.
The company's existing shareholders Lilly Asia Ventures, Temasek Holdings, Qiming Venture Partners, Hankang Capital and CICC Capital also joined the round.
Based in Shanghai, Abbisko focuses on cancer-related researches and therapy development with an extensive small molecule pipeline in oncology targeted therapy and immune-oncology areas.
The company, which did not disclose its valuation in the fundraising, said the proceeds will be used to accelerate the progress of its clinical programmes and further expand its preclinical pipeline.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
